NCT02775916View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

May 17, 2017

Study Completion Date

May 17, 2017

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

CDZ173

DRUG

Placebo

Trial Locations (2)

4032

Novartis Investigative Site, Debrecen

10117

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY